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Retinal pigment epithelium (RPE) 
has an essential role in ocular phar-
macokinetics. In this study an in 
vitro model of RPE was character-
ized. The barrier properties and 
active transport between the model 
and ex vivo tissue were comparable. 
Expression of eight efflux transport-
ers was studied in four different 
RPE models. Multidrug resistance 
associated proteins 1, 4 and 5 were 
constantly expressed. In addition, 
literature data of influx transport-
ers of RPE models and RPE in vivo 
is summarized and the role of mem-
brane transporters in ocular phar-
macokinetics discussed. 
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ABSTRACT
The posterior location and the blood-retinal barrier (BRB) make drug delivery in diseases affecting retina
and vitreous challenging. The outer part of BRB is composed of retinal pigment epithelium (RPE), which
restricts drug entry to the retina from the systemic circulation and from the periocular space. In this
study, filter grown ARPE-19 cells have been characterized as a potential in vitro model of the human RPE
for use in drug delivery studies. ARPE-19 barrier properties were evaluated in different culture
conditions.  The  ARPE-19  model  was  3-17  times  more  permeable  than  isolated  bovine  RPE-choroid
tissue, but the ARPE-19 model efficiently separated test compounds based on their lipophilicity and
molecular sizes. Expression of RPE related genes, RPE65, CRALBP, TRP1, tyrosinase and Mitf-A and OTX2
transcription factors was greatly enhanced by filter culture. It has become evident that transporters play
an important role in pharmacokinetics. The expression of efflux proteins, p-glycoprotein (P-gp),
multidrug resistance associated proteins 1-6 (MRP) and breast cancer related protein (BCRP), in various
RPE cell lines was studied. As with primary RPE cells, ARPE-19 cells express MRP1, MRP4 and MRP5
efflux proteins. Efflux protein activity was evaluated in cellular uptake studies using calcein-AM and
carboxydichorofluorescein as probe molecules, and by bi-directional permeability studies.  The studies
indicate MRP1 and MRP5 activity in ARPE-19 cell line. Active transport in the ARPE-19 cell model was
qualitatively, though not quantitatively similar, with isolated RPE-choroid tissue. Furthermore, non-viral
gene transfer was studied in the ARPE-19 cell model. Prolonged gene expression was achieved by
liposomal carriers. In conclusion, the ARPE-19 cell model can be used to screen drug molecules with
different physicochemical properties and in gene delivery studies. The greater passive permeability may
lead to an underestimation of active transport in this model. Several membrane transporters are
expressed and active in the ARPE-19 cell model.
National Library of Medicine Classification: QS 525, QU 55.7, QW 38, QZ 52, WW 103
Medical Subject Headings: Blood-Retinal Barrier; Cell Culture Techniques; Drug Delivery Systems; Gene
Therapy; Gene Transfer Techniques; Membrane Transport Proteins; Pharmacokinetics; Retinal Pigment
Epithelium
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TIIVISTELMÄ
Silmän takaosan sairauksien lääkehoito on haasteellista. Veriverkkokalvo-este rajoittaa aineiden
siirtymistä verenkierrosta ja silmän viereen annostelussa. Verkkokalvon pigmenttiepiteelisolut
muodostavat ulomman osan veriverkkokalvo-esteestä. Tässä tutkimuksessa selvitettiin verkkokalvon
pigmenttiepiteelisolulinjan, membraanille kasvatettujan ARPE-19 solujen, soveltumista
lääketutkimukseen. Solumaton tiiviyttä tutkittiin eri kasvatusolosuhteissa ja verrattiin naudasta
irroitettuun suonikalvo-verkkokalvon pigmenttiepiteelikudokseen. Tulokset osoittivat, että solumalli oli
3-17 kertaa vuotavampi, mutta pystyi erottelemaan aineet molekyylikoon ja rasvaliukoisuuden
perusteella. Lisäksi eri kasvatusolosuhteita testatessa havaittiin, että membraanikasvatuksessa
pigmenttiepiteelille tyypillisten geenien ekspressoituminen nousee selvästi. Viime vuosikymmenen
aikana on tullut ilmeiseksi, että membraanikuljettimilla, jotka aktiivisesti kuljettavat aineita solukalvojen
läpi, on tärkeä rooli lääkeaineiden farmakokinetiikassa. Tässä työssä mitattiin aineita solusta ulospäin
kuljettavien P-gp:n (p-glycoprotein), MRP:n (multidrug resistance associated proteins 1-6) ja BCRP:n
(breast cancer related protein) ilmentymistä useassa verkkokalvon pigmenttiepiteelin solulinjassa. ARPE-
19 soluissa, kuten myös ihmisperäisissä primaari pigmenttiepiteelisoluissa ilmentyivät MRP1, MRP4 ja
MRP5. Aktiivisuuskokeet osoittivat, että MRP1 ja MRP5 ovat todennäköisesti myös aktiivisia ARPE-19
soluissa. Suuntakokeissa tulokset solumallin ja kudoksen välillä olivat samansuuntaisia, joskin
kudoksessa suuntaerot tulivat huomattavasti selvemmin esille. Solumallia käytettiin myös
viruksettomien geenikuljettimien testaamiseen. Pigmenttiepiteelin solut ovat normaalitilanteessa
jakautumaton soluja, joten voi olla mahdollista, että polarisoitunut solumalli vastaa verkkokalvon
pigmenttiepiteelin soluja todellisuudessa paremmin kuin yleensä käytetyt jakautuvat solut.  Kun ARPE-
19 solut transfektoitiin liposomikantajilla, markkerigeeni ilmentyi yli kahden kuukauden ajan.
Yhteenvetona voidaan todeta, että ARPE-19 solumallia voidaan käyttää fysikokemiallisilta
ominaisuuksiltaan erilaisten lääkeaineiden testaukseen, mutta solumallin suurempi passiivinen
läpäisevyys kudokseen verrattuna voi peittää alleen aktiivisen kuljetuksen. Pigmentin puute rajoittaa
käyttöä pigmenttiin sitoutuvien aineiden testaukseen. Useat membraanikuljettimet ilmentyvät ja ovat
aktiivisia ARPE-19 solumallissa.
Yleinen suomalainen asiasanasto (YSA): epiteeli, farmakokinetiikka, geenitekniikka, geeniterapia,
lääkehoito, proteiinit, verkkokalvo
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OTX2 homeodomain-containing transcription factor
PCR polymerase chain reaction
PEI polyethylene imine
P-gp p-glycoprotein
POS photoreceptor outer segments
PBS phosphate buffered saline
qRT-PCR quantitative reverse transcriptase polymerase chain reaction
ROS rod outer segment
RPE retinal pigment epithelium
RPE-J rat derived retinal pigment epithelium cell line
RPE65 retinal pigment epithelium specific gene 65 kDa
RFT-1 folate transporter protein
SEAP secreted alkaline phosphatase
SLC solute carrier family
TEP transepithelial potential
TER transepithelial resistance
TLR-4 toll like receptor 4
TRP tyrosinase related protein
VEGF vascular endothelial growth factor
1 INTRODUCTION
Many vision threatening diseases affect the posterior eye segment. These include age-related macular
degeneration (AMD), diabetic retinopathy, glaucoma, retinal venous and arterial occlusive diseases,
inherited retinal degenerations and posterior uveitis. In the western world over 60% of visual
impairment in the elderly is caused by AMD, whereas in the working age population diabetic retinopathy
and inherited retinal degenerations are common causes of visual impairment.
 It is estimated that 50 million people all over the world are affected by AMD, and roughly one third of
the patients are legally blind (vision in the better eye below 0.3 in Snelle’s chart).   It  is  estimated that
number of people suffering from AMD will increase significantly during next decades due to the
increased aging of population (Rein et al. 2009).  The central vision is affected in AMD, which leads to
difficulties in reading, writing and recognizing faces. The peripheral vision remains mainly un-affected,
but the quality of life is seriously affected by advanced forms of AMD. The pathophysiological
mechanisms leading to changes in macular region are still largely unknown. Both environmental (eg.
cigarette smoking) and genetic factors play roles in the development of AMD (Ding et al. 2009,
Vingerling  et  al.  1996,  Thakkinstian  et  al.  2006).  AMD  is  divided  into  atrophic  and  exudative  forms.
Approximately 80-90% of the patients suffer from the atrophic form of AMD. Odema and bleeding with
rapid change in visual acuity are symptoms of the exudative form of the disease. Increased levels of
vascular endothelial growth factor (VEGF) have been associated with the progression of the exudative
AMD, and during the last years, VEGF inhibitors have been launched as a new effective treatment in the
exudative form of AMD. In contrast, there are no effective treatment options for people suffering from
the atrophic form of AMD.
Understanding the pathophysiological and molecular mechanisms of vision threatening diseases is
crucial in the discovery of new potential drug molecules. But the drugs must be also efficiently delivered
to the posterior eye segment targets. The posterior eye segment is a demanding tissue from the drug
delivery point of view because of its posterior location. Furthermore, retina and vitreous are protected
by blood-ocular barriers (blood-aqueous and blood-retinal barrier), similarly as brain is protected by
blood-brain barrier (Hornof et al. 2005). The blood-retinal barrier is composed of retinal pigment
epithelium (RPE) and endothelial cells of the retinal capillaries (Cunha-Vaz 2004). RPE is a tight selective
cell monolayer between the retina and choroidal blood circulation. The drug entry to retina and vitreous
is restricted by RPE after systemic and periocular drug administration. Furthermore, some drugs are
2eliminated from vitreous through RPE. Overall, the RPE plays an essential role in the posterior segment
pharmacokinetics, but many aspects remain unknown. For example, the role and expression of
membrane transporters in the RPE are poorly understood. The emerging role of membrane transporters
in drug delivery and in drug efficacy has become evident during the last decade (Dobson and Kell 2008).
Currently drug delivery to the vitreous and retina is mainly achieved by repeated intravitreal injections.
Unfortunetely, many posterior segment diseases require long time periods of medical therapy. Thus,
prolonged action drug delivery methods would decrease the number of injections needed. One
possibility is gene transfer to ocular cells eg. to RPE cells. The transfected RPE cell could then secrete
therapeutic proteins such as growth factors apically (to the retina) or basolaterally (to the choiroid).  In
this study, polarized, non-dividing RPE cells were transfected with different non-viral gene delivery
systems.
Cell models are useful in pathophysiology and molecular studies of diseases. They can be used also to
investigate ADME (drug absorption, distribution, metabolism and elimination) properties of drugs and
drug delivery systems (Hornof et al. 2005). The limited availability of human ocular tissue emphasizes
the value of the ocular cell models. Currently there is no established culture model for human RPE, even
though such a model would be a very useful tool in ocular drug delivery studies.  In this work, the
polarized RPE cell model, ARPE-19, was characterized as potential tool for ocular drug delivery studies.
32       REVIEW OF THE LITERATURE
2.1  Anatomy and physiology of the posterior eye
Figure 1. Structure of the eye and tissue layers in the posterior part of the eye. Modified from Hornof et
al. 2005 and Steuer et al. 2004.
The retina is protected by inner and outer blood-retinal barriers (BRB). The inner part is composed by
the endothelial cell layer of retinal capillaries and the outer part by retinal pigment epithelium, a tight
monolayer of epithelial cells. Neural retina has high metabolic activity and this is dependent on the
ability of retinal capillaries to deliver nutrients and oxygen to the inner two thirds of the neural retina.
The outer third of neural retina and RPE are nourished by the blood supply from choriocapillaries,
fenestrated capillaries located underneath the RPE (Fig. 1).Metabolic waste products are transported
from the neural retina to retinal and choroidal blood circulation through inner and outer BRB,
respectively (Strauss 2005). The higher oncotic pressure in choroid drives water from the neural retina
towards the choroid. The pressure inherent in the water flow holds the retinal layers together and in
close contact with the choroid. Higher oxygen content in the choroid compared to the retinal vessels
ensures that there is an adequate oxygen supply to the retina.
4Photoreceptors, rod and cones, are located in the outermost layer of the neural retina. The outer
limiting membrane is pierced by the inner segments of the photoreceptors. The outer segments of
photoreceptors (POS) are located between apical microvillae of retinal pigment epithelium (RPE) cells.
RPE  is  a  key  player  in  maintaining  a  healthy  retina.  POS,  which  are  shed  from  photoreceptors  in  a
circadian rhythm, are phagocytosed and metabolized by the RPE cells.  RPE is constantly exposed to
oxidative stress caused by the high oxygen concentration, extensive light exposure, metabolic load of
modified lipids from POS and lipofuscin accumulation (Beatty et al. 2000). RPE participates in the visual
cycle: vitamin A is recycled back to photoreceptors after being processed in the RPE cells. RPE also
produces and releases growth factors including pigment epithelium derived growth factor (PEDF),
vascular endothelial growth factor (VEGF) and ciliary neurotrophic factor (CNTF) (Strauss 2005). PEDF is
mainly secreted apically towards neural retina and VEGF basolaterally towards choriocapillaris (Becerra
et al. 2004, Blaauwgeers et al. 1999). RPE differ from other epithelia in that Na+, K+ ATPase is found in
the apical membrane and N-cadherin instead of E-cadherin is located in cell-to-cell junctions (Gundersen
et al. 1991, Okami et al., 1990, Youn et al. 2006).
Choroid is composed of suprachoroid, choroidal vessels, choriocapillaries and Bruch’s membrane. The
suprachoroid is an avascular space containing the extracellular matrix and melanocytes between sclera
and choroidal vessels. Large choroidal vessels are found in Haller’s layer and smaller and middle sized
vessels in Sattler’s layer. Choriocapillary layer is composed of lobes, where the artery is located in the
middle of the lobe and the veins are situated on the borders of the lobes. In the macula the diameter of
choriocapillaries is circa 7 µm and in peripheral retina it is between 10-50 µm (Richard 1992, Spraul et al.
2002). The capillaries are fenestrated with windows of 55-80 nm in diameter on the Bruch’s membrane
side of the capillaries (Guymer et al. 2004, Torczynski 1995). Bruchs’s membrane is located between
choriocapillaries and RPE and it is composed of two collagen layers and separated by the middle elastic
layer. The innermost layer of Bruch’s membrane serves as the basement membrane for RPE cells.
Sclera is an avascular membrane of varying thickness at different locations. In humans, it is thinnest at
the equator 0.39±0.17 mm, 0.53±0.14 mm at corneoscleral junction (limbus) and near to the optic nerve
its thickness is 0.9-1.0 mm (Olsen et al. 1998). The surface area of human sclera is 16-17 cm2 (Olsen et al.
1998). It is composed of three layers: episclera, stroma and lamina fuscia. Episclera is continuous with
Tenon’s capsule which extends from the limbus to the optic nerve. These two fibrous membrane
structures are connected by the connective tissue. The periocular space is the potential space between
Tenon’s capsule and the sclera. Episcleral, conjunctival vessels including lymphatic vessels are found in
5episclera. The stroma is composed of collagen (75% of dry weight, mainly type I), proteoglycans, a few
fibroblasts and elastic fibers (Geroski and Edelhauser 2001). Melanocytes are found in thin lamina fusca,
which is in tight contact with choroid. The eyeball is further surrounded by six eye muscles, fat,
connective tissue and bones forming the orbit.
2.2  Drug delivery to retina
Generally it is not possible to achieve adequate drug concentrations in the posterior eye segment by
topical administration of eyedrops. Most of the drug is cleared away by drainage of the instilled solution
and  systemic  conjunctival  drug  absorption  even  before  the  drug  reaches  the  cornea  or  anterior
chamber. Low drug diffusion in the lens and the flow of aqueous humor (in the posterior to anterior
direction) further hinder drug access to the retina.
Currently, drug acces to retina and vitreous is achieved mainly either by systemic administration or by
intravitreal injections (Fig. 2: A and B). With systemic delivery, it is difficult to achieve adequate drug
concentrations in the retina and high systemic doses may cause adverse effects (e.g. in the case of per
oral carbonic anhydrase inhibitors). Corticosteroids, immunosuppressive agents, and antibiotics in
severe infections are used per orally for the treatment of posterior segment eye diseases.
The clinical use of intravitreal injections increased rapidly after the launch of the VEGF-inhibitors for the
treatment of exudative form of AMD. These drugs are usually well tolerated and the treatment results
with VEGF-antibodies are generally good. The invasive nature of the procedure may lead to retinal
detachment, endophthalmitis and vitreous hemorrhage, though fortunately these adverse reactions are
rare. In many cases frequent injections for an indefinite period of time are needed in the treatment. The
growing number of the injections is a load on physicians in eye clinics and their long term safety is
unknown.  Prolonged action formulations would decrease the number of injections needed.
Periocular injections, which include subconjunctival, sub-Tenon, peribulbar and retrobulbar injections,
are mainly used in the clinics to deliver local anesthetics. Due to its accessibility, relatively high
permeability even to macromolecules (mw 70-150 kDa) and the large surface area of sclera (Amaral et
al. 2005, Ambati et al. 2000a, Ambati et al. 2000b), the transscleral drug delivery has gained interest as
an alternative route of drug delivery (Fig. 2: C). However, transscleral delivery is limited by several
membrane barriers (sclera, choroid and RPE) and dynamic factors (episcleral blood flow, choroidal
6circulation, membrane transporters, metabolic enzymes, drug binding and pressure related matters)
which complicate drug delivery by the transscleral route (Fig. 2: C).
Figure 2. Direction of drug permeation after intravitreal (A), systemic (B) and transscleral (C) drug
delivery.  RPE plays an important role in drug clearance after intravitreal injections (A) and it is a
significant permeation barrier to systemic (B) and in transscleral (C) drug delivery to posterior eye
segment.
2.2.1. Passive permeability of sclera, choroid and retinal pigment epithelium
Scleral permeability has been extensively studied (Ambati et al 2000a, Olsen et al 1995, Prausnitz and
Noonan 1998) whereas the RPE permeability has been systemically studied only in recent times. An
inverse correlation was found in both layers between molecular diameter and permeability (Prausnitz
and Noonan 1998, Pitkänen et al. 2005). In sclera, passive diffusion takes place mainly via the
interfibrillar aqueous pathway (Geroski and Edelhauser 2001). Rabbit sclera has been observed to be
permeable even to 150 kDa IgG molecules and 70 kDa FITC-dextran has been able to diffuse through
human sclera (Ambati et al. 2000a, Olsen et al. 1995).  Sclera has been shown to be more permeable to
negatively than positively charged molecules and this has been suggested to be a consequence of the
presence of negatively charged proteoglycans in the sclera (Maurice and Polgar 1977).  Pitkänen et al.
studied RPE permeability using isolated bovine RPE-choroid tissue. For lipophilic drugs permeability in
sclera  and  RPE  was  similar  but  this  was  not  the  case  for  hydrophilic  drugs  and  macromolecules,  RPE
7being revealed to be 10-100 times less permeable than sclera (Pitkänen et al. 2005). Selected examples
are given in Table 1.
Table 1. Permeability of sclera and RPE-choroid
Permeability*10-7cm/s
     mw log D Scleraa RPE-choroidb ratioc
6-CF      376 -3.14 100     9.6   10.5
Nadolol      309 -1.06 394   22.4   17.6
Timolol      316   0.09 408 145.0     2.8
FITC-dextran 40 000    n.d.    49     0.5 106.5
mw; molecular weight, log D; logarithm of the apparent distribution coefficient between n-octanol and water at pH 7.4. LogD
values from the literature (6-CF (Araie and Maurice 1987), nadolol and timolol (Pitkänen et al. 2005))aPrausnitz and Noonan
1998 and Prausnitz 1998 b. bPitkänen et al. 2005 cScleral permeability/RPE-choroid permeability.
Bruch’s membrane preparations from young human donors were found to be permeable to proteins
exceeding mw of 200 kDa. A decline in permeability was seen in the membranes from older donors but
even these membranes were permeable to macromolecules of 100 kDa (Moore and Clover 2001).
Compared to RPE Bruch’s membrane can be considered to be an insignificant permeation barrier.
Interestingly, decreased permeability with increasing lipophilicity was observed in the bovine choroid
(including Bruch’s membrane) preparations which could be a consequence of binding to melanin and
lipids in the choroid (Cheruvu and Kompella 2006, Cheruvu et al. 2008).
2.2.2 Transscleral drug delivery
In transscleral delivery the drug is administered by periocular injections, or this can be achieved by
placing some kind of controlled release system in the periocular space. Significant drug loss has been
observed in vivo in animal models due to episcleral, conjunctival blood and lymphatic flow in periocular
drug delivery (Kim et al. 2004, Robinson et al. 2006). Kim et al. used a periocular implant containing
hydrophilic gadolinium-DTPA (mw 938 Da) in rabbits and measured tracer concentrations in vitreous
using magnetic resonance imaging (Kim et al. 2004).  Only 0.06% of the released drug was detected in
vitreous during 8 hours and a high concentration of gadolinium-DTPA was found in the buccal lymph
nodes. The experimental set up was repeated ex vivo and the vitreal tracer concentrations were 30
times higher than in vivo. Drug loss from the periocular space was also studied by Robinson et al. (2006).
8After sub-Tenon injection in rabbits triamcinolone acetonide could be detected in the vitreous only if the
lymphatic flow and conjunctival blood flow had been blocked by immediate euthanasia after injection or
destruction of conjunctival and lymphatic vessels by ‘conjunctival window’ incision (Robinson et al.
2006). To overcome the problem of periocular loss, intrascleral implants, or implant with a drug
releasing surface towards retina have been tested in animal models and significantly higher vitreal drug
concentrations were obtained with these formulations compared to periocular injections (Kato et al.
2004, Okabe et al. 2003, Pontes de Carvalho et al. 2006).
After scleral  permeation the drug may be cleared by the choroidal  circulation. About 85% of the total
blood flow into the eye passes into the choroidal circulation (Bill 1975). From a pulsatile ocular blood
flow measurements, it can be estimated that blood flow rate in choroid is on average 1 ml/min/choroid,
which if considered in proportion of the size of the choroid, is one of the highest values in the human
body  (Aydin  et  al.  2003,  Yang  et  al.  1997).  The  permeability  of  fenestrated  choriocapillaries  has  been
studied in cats and rabbits (Bill 1968, Tornquist et al. 1979, Bill et al., 1980). The permeability is high for
small molecules like sodium and EDTA 70-180*10-5 cm/s but less for larger myoglobin (17 kDa), albumin
(67 kDa) and gammaglobulin (160 kDa) 0.017-0.54*10-5 cm/s  (Bill  1968,  Tornquist  et  al.  1979).  Small
molecules in the choriocapillaries equilibrate rapidly with the extracellular tissue. Thus choriocapillaries
may serve as a sink for small molecules and it is believed that the clearance for small molecules is faster
than for the larger ones. The contribution of drug clearance by choroidal blood flow in transscleral
delivery is unknown. In the study by Robinson et al., inhibition of choroidal blood flow by cryotherapy
did not result in detectable drug concentrations in vitreous (Robinson et al. 2006).  There are also other
flow  and  pressure  related  factors  that  may  be  relevant  to  transscleral  delivery  such  as  uveoscleral
outflow  from  suprachoroidal  space  through  sclera  to  the  conjunctival  lymphatic  system  (Kim  et  al.
2007).
2.2.3 Drug delivery by intravitreal injections
Intravitreal injections result in high drug concentrations in vitreous and retina.  Typical drug molecules
(mw below 500 Da) distribute equally in vitreous during the first couple of hours after intravitreal
injection (Maurice and Mishima 1984). The main components of vitreous are water (>98%), types II, V/XI
and IX collagens and hyaluronan (Bishop 2000). Neural retina including the inner limiting membrane also
contains hyaluronan as well as heparan sulfate, chondroitin sulfate and dermatan sulfate, which are
9negatively charged (Goes et al. 1999, Inatani and Tanihara 2002).  This leads to aggregation and poor
penetrations of cationic drugs and particles (Kim et al. 2009, Pitkänen et al. 2003). Jackson et al. found
that molecules smaller than 76.5±1.5 kDa are able to freely diffuse through neural retina (Jackson et al.
2003). Drugs are cleared from vitreous by the anterior and by posterior routes usually according to first
order kinetics i.e. elimination rate is proportional to remaining drug concentration. All drugs are cleared
by the anterior route, from anterior vitreous through the posterior and anterior chambers to Schlemm’s
canal and aqueous and episcleral veins (Fig. 3). The drugs that are either sufficiently lipophilic or
substrates of transporters located in BRB are also cleared by the posterior route (Fig. 3), which shortens
their vitreal half-life.
Figure 3. Clearance of drug from vitreous after intravitreal injection at the pars plana (arrow). All drugs
are cleared by the anterior route, through posterior and anterior chamber and trabecular meshwork to
Schlemm’s canal (A).  Lipophilic drugs and those drugs which are substrates of transporters in outer BRB
are also cleared from the posterior route across the RPE (B). Modified from Hornof et al. 2005.
For example, the vitreal half-life of penicillin and carbenicillin, which are actively transported through
RPE, is about 3 hours, whereas gentamycin and streptomycin are cleared only via the anterior route and
they have half-lives of 14-18 hours (Maurice and Mishima 1984, Barza et al. 1983). Hydrophilicity and a
large molecular weight decrease drug clearance from the vitreous. Mordenti et al. compared the half-
lives of full sized human epidermal growth factor receptor 2 antibody (150 kDa) and its fab fragment (48
kDa) in monkeys and reported half-lives of 5.6 and 3.2 days, respectively (Mordenti et al. 1999). These
sizes are very similar to currently used VEGF inhibitors, ranibizumab (Fab fragment) and bevasitzumab
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(whole antibody). It is also worth noting that the rate of clearance is faster after vitrectomy (Chin et al.
2005, Mason et al. 2004, Moritera et al, 1991).
2.2.4 Prolonged action drug delivery systems
Chronic posterior segment diseases may require prolonged medication, perhaps for the rest of the
patient’s life. Therefore, dosing frequency becomes an important issue, especially in invasive drug
administration. Prolonged action drug delivery systems would decrease the frequency of dosing. Tis
kinds of drug delivery systems could be placed periocularly, inside the sclera or intravitreally. There are
different types of prolonged drug delivery systems e.g. biodegradable and non-biodegradable solid
implants, injectable polymers, micro- and nanoparticulates and liposomes.  In addition, gene therapy
can result in long lasting therapeutic protein secretion.
The rate of drug release can be controlled more precisely with non-biodegradable implants. Initial and
final drug burst often seen with biodegradable implants can sometimes cause adverse effects. Both
implant types are placed into the vitreous cavity at the pars plana. The implant must be tied with
surgical thread to avoid its uncontrolled movements in the vitreous cavity. Biodegradable implants do
not need to be removed. Intravitreal non-biodegradable implants containing ganciclovir (Vitrasert) and
fluorocinolone acetonide (Retisert) are already in clinical use to treat cytomegalovirus infection and
posterior uveitis, respectively (both developed by Bauch & Lomb, Rochester, NY, USA). A biodegradable
poly(lactic-co-glycolic acid) (PLGA) based implant that releases dexamethasone (Posurdex, Allergan Inc.,
Irvine, CA, USA) is in clinical trials to treat uveitis and diabetic macular edema. Estimates for the
durations of action are 8, 30 and 1.5-6 months for Vitrasert, Retisert and Posurdex, respectively (Del
Amo and Urtti 2008).
Injectable systems, which include injectable polymers, micro- and nanoparticulates, liposomes and gene
delivery complexes, are less invasive than implants. Currently these are not in clinical use. In the case of
in situ gelling system, the polymer can be injected to the desired site, where changes in temperature, pH
or ion concentration may cause a phase transition to semi-solid or solid form (Vehanen et al. 2008) .
Particulate systems include nano- and micro sized particles where the drug is either inside the polymer
cavity (capsules) or within polymer (spheres) (Bejjani et al. 2005, Bourges et al. 2003, Herrero-Vanrell
and Refojo 2001, Moshfeghi and Peyman 2005). In both intravitreal and transscleral administration, the
pharmacokinetics of the particulate system is affected by the nature of the polymer and its molecular
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weight (Amrite et al. 2008, Sakurai et al. 2001). Studies have shown that intravitreally administered
nanoparticles may be taken up by the RPE cells (Bejjani et al. 2005, Bourges et al. 2003, Kimura et al.
1994). The duration of action of these drug delivery systems varies from 24 hours to months (Del Amo
and Urtti 2008).
In gene transfer the DNA is transferred into the ocular cells that will produce the protein for as long as
the transgene is transcribed and translated to protein. Gene transfer can be accomplished with viral and
non-viral gene delivery systems. The natural infectious character of viruses is utilized in viral vectors,
while non-viral systems are based on physicochemical interactions between DNA, the carrier material
and biological membranes.  Viruses for gene-therapy include adeno-, adenoassociated (AAV)-, baculo-,
retro- and herpes simplex viruses. The carriers in non-viral gene transfer include cationic liposomes,
polymers and peptides. Some viral vectors (AAV, retro- and lentiviral) are capable of integrating DNA
permanently into the host genome, but unfortunately the integration is not site-controlled and this may
lead to malignancies (Romano et al. 2009). Non-viral vectors are typically less efficient in transfecting
than the viral vectors, the duration of transgene expression is short, since they do not generally
integrate DNA into genome, but they are less immunogenic, large scale production is possible and there
are  no  strict  size  limitations  for  the  transgene.  Many  ophthalmic  target  cells  are  differentiated,  non-
dividing cells, e.g. RPE cells and photoreceptors. With the exception of retroviruses,viruses are capable
of transducing non-dividing cells, but the efficacy of non-viral systems is low in non-dividing cells (Magin-
Lachmann et al. 2004, Toropainen et al. 2007). This is partly due to lack of cell division and opening of
the nuclear envelope in differentiated cells (Ludtke et al. 2002). It has been shown previously that
vitreous and neural retina are significant barriers to intravitreal gene delivery of non-viral vectors due to
binding of cationic complexes to negative structures of vitreous and neural retina (Pitkänen et al. 2003,
Pitkänen et al. 2004, Peeters et al. 2005).
In the cell encapsulation technique, the dividing cells are stably transfected in vitro and subsequently
they are encapsulated and delivered in this form to the target tissue. Retinal pigment epithelial cell line
(ARPE-19) seems to be viable in the microencapsulated form and able to secrete the transfected gene
products over prolonged periods (Wikström et al. 2008). NT501 (Neurotech Inc., USA) is a polymer
implant that contains CNTF transfected ARPE-19 cells. The product is in clinical trials to treat retinitis
pigmentosa patients (Sieving et al. 2006).
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2.3 Role of transporters in the outer blood-retinal barrier
Drug transfer through cell membranes and epithelial tissues depends on the passive permeability and
active transport processes. Passive drug permeation is determined by the physical and chemical features
of the drug (e.g. lipophilicity, hydrogen bonding capacity, charge, molecular weight). Passive permeation
is driven by the concentration gradient of the drug while active transport can move the compound even
against a concentration gradient. Active transport depends on the affinity of the drug for the
transporter, and on the number of the transporters in the cell membrane. The driving force of active
transport can be energy from ATP hydrolysis, pH gradient or ion gradient (e.g. Na+, H+).  Transporters are
integral membrane proteins that can be divided into influx and efflux transporters. Influx transporters
transfer  drugs  from  the  extracellular  space  into  the  cell,  while  efflux  transporters  act  in  opposite
direction. Currently there are almost 400 genes encoding members of solute carrier (SLC) transporter
family (Fredriksson et al. 2008) with these being divided into 46 subfamilies.
Transporters have important role in many tissues like brain, liver, kidney and small intestine. The
transporters have their own distinct substrates e.g. nutrients, waste products and xenobiotics which
they carry across the cell membranes. Typical substrates include amino acids, peptides,
neurotransmitters, monocarboxylates, organic anions and organic cations, various vitamins and metal
anions (Fredriksson et al. 2008, Hediger et al. 2004). Due to the large number of transporters and their
broad  substrate  variety,  it  is  evident  that  membrane  transporters  are  much  more  relevant  in
pharmacokinetics than had been previously estimated (Cascorbi 2006, Dobson and Kell 2008, Maeda
and Sugiyama 2008, Mizuno et al. 2003).
Depending on the transporter localization and direction of the transporter process, active transport may
either enhance or restrict the access of the drug to its site of action. Sometimes competition for the
same transporter or induction of the transporter may lead to drug-drug –interactions.  Polymorphism is
prevalent in the drug transporter genes, and sometimes this can account for inter-individual
pharmacokinetic differences (Zhou et al. 2008).
Little is known about which transporters are present in the eye, and their role in ocular drug delivery is
poorly understood. Fig. 4 illustrates the possible consequences of the membrane transporter activity in
the RPE. The emerging role of transporters in ocular drug delivery has been summarized in publication
V.
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Figure 4.  Possible roles of the transporters in RPE. Transporters on the choroidal side of the RPE are
expected to facilitate (influx transporters) or restrict (efflux pumps) drug transfer from the choroidal
circulation to the retina. From the vitreal side, influx and efflux proteins can either increase or decrease
the intravitreal half- life of the drugs, respectively.
2.3.1 ATP binding cassette efflux transporters
ATP binding cassette (ABC) efflux proteins transport their substrates from the cell interior across cellular
plasma membranes to the extracellular space. Currently, there are 49 human ABC efflux transporter
genes subdivided into 8 subfamilies (Vasiliou et al. 2009). The most widely studied efflux transporters
include p-glycoprotein (p-gp, ABCG1, encoded by multi drug resistance protein 1 (MDR1)- gene),
multidrug resistance associated proteins 1-6 (MRPs, ABCC1-6) and breast cancer resistance protein
(BCRP, ABCG2). P-gp consists of 12 transmembrane segments and two nucleotide binding domains
(Schinkel and Jonker 2003). The structure of the MRPs is similar with the exception that MRP1-3, 6 and 7
have an additional N-terminal transmembrane domain containing five transmembrane segments
(Deeley  et  al.  2006,  Schinkel  and  Jonker,  2003).  BCRP  is  a  half  transporter  with  six  transmembrane
segments and a single nucleotide binding domain (Haimeur et al. 2004). In order to function as a
transporter, two BCRP proteins must dimerize. Information about tissue expression, membrane
localization (apical, basolateral or both) and examples of substrates and inhibitors has been summarised
in Table 2.
The efflux proteins have a protective role in various tissues (brain, placenta), they are involved in the
elimination of many diverse substances (e.g. in kidney, liver) and in many other physiological functions
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(Kusuhara and Sugiyama 2009, Nies et al. 2004, Zhang et al. 2004, Young et al., 2003). The substrate
specifity between the ABC efflux transporters is partly overlapping, and therefore it is difficult to predict
their impact in pharmacokinetics. Furthermore, many cell lines express several efflux transporters,
which makes the analysis of the results challenging. In addition, there are often differences between
species in expression and functionality. Caution must be exercised in extrapolating results obtained in
animal studies to humans with respect to their expression and action. The expression of some of the
efflux transporters can be induced by the drug treatment and some efflux transporters have been
associated with multi drug resistance, typically found in cancer tissue.
2.3.2 ATP binding cassette efflux transporters in retinal pigment epithelium
The results concerning p-gp expression in RPE are partly controversial. In one of the first studies, p-gp
expression was detected only after daunomycin exposure (Esser et al. 1998). Later p-gp was found both
in apical and basolateral membranes of human RPE (Kennedy and Mangini 2002). The authors suggested
that there are different roles for basolaterally and apically located p-gp. In the study of Steuer et al.,  p-
gp was found in porcine RPE (the localization on the plasma membranes was not studied) and in
permeability studies with two p-gp substrates, rhodamine 123 and verapamil, the active transport was
detected to be in the choroidal direction (Steuer et al. 2005). P-gp expression have been also studied in
RPE  cell  lines:  low  expression  of  p-gp  was  found  in  h1RPE  and  D407  cells,  but  not  in  ARPE-19  cells
(Constable et al. 2006). In the same study cellular uptake of p-gp substrate rhodamine 123 was detected
only in the D407 cell line.
MRP1 has been detected in primary human RPE cells, ARPE-19 cells and in porcine RPE tissue (Steuer et
al. 2005, Aukunuru et al. 2001). The MRP1 substrate, fluorescein, was transported in porcine RPE-
choroid tissue in the choroidal direction (Steuer et al. 2005). MRP5 expression at the mRNA level has
been found in ARPE-19 cells (Cai and Del Priore 2006). Stojic et al studied MRP5 splice variant expression
and found three shorter splice variants (SV1-3) in addition to the full length MRP5 transcript in human
RPE (Stojic et al. 2007).  SV2 isoform expression was confirmed by immunohistochemistry in the apical
and basolateral surface of mouse RPE. The MRP6 transcript expression was found in patients with
pseudoxanthoma elasticum in the retina,  but not in RPE (Bergen et al.  2000, Scheffer et al.  2002).  The
expression of MRP2, MRP3, MRP4 or BCRP have not been studied in RPE.
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2.4 In vitro models to estimate drug delivery in outer blood-retinal barrier
Differentiated organotypic cell models are important tools in biology. They allow experiments with well-
defined conditions and mechanistic studies related to cell biology, physiology, toxicology and
pathophysiology. ADME related experiments with differentiated cell models are currently an important
part in drug discovery and development  programmes (Hornof et al., 2005). In drug development,
various ADME cell models (e.g. intestinal, BRB, placenta, skin) are used to screen drug candidates and
drug delivery systems.
Despite its importance, there is no established cell model available for the outer BRB. In principle, such
models could be based on isolated tissues or cell cultures. Isolated tissue represents the integrity and
expression levels of its in vivo counterpart, but this approach is tedious and it is not suitable for large-
scale routine use. The cell lines express human proteins, they are suitable for routine use, but
establishment of the cell model requires detailed  characterization of the morphology, barrier
properties, and an awareness of gene expression properties.
2.4.1 Isolated retinal pigment epithelium tissues
Due to the limited availability of human material, isolated human RPE(-choroid) tissue are rarely used,
instead isolated RPE(-choroid) tissues are mainly from porcine, bovine or rabbits (Pitkänen et al. 2005,
Steuer et al. 2005, Arndt et al. 2001, Edelman and Miller 1991, Frambach et al. 1988, Kansara and Mitra
2006). During the experimentsseveral electrical parameters eg. transepithelial resistance (TER) and
transepithelial potential (TEP) can be monitored to confirm that the membrane is intact and viable.
Isolated RPE tissues always contain parts of the choroid (Bruch’s membrane) since it is impossible to
separate a pure RPE cell layer without disturbing the integrity of the cell layer. However the contribution
of Bruch’s membrane to TER is negligible (Miller and Edelman 1990). The integrity may be easily
compromised in the isolation process and the specimens must be used rapidly after isolation if they are
to maintain their viability. There is extensive variation in the measured TER values from different
species: bovine 100-260 ?*cm2 (Pitkänen  et  al.  2005,  Arndt  et  al.  2001,  Edelman  and  Miller  1991),
rabbits 82-350 ?*cm2 (Frambach et al. 1988, Kansara and Mitra 2006), porcine ~260 ?*cm2 (Arndt et al.
2001) and human 36-148 ?*cm2 (Quinn and Miller 1992).
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Isolated RPE-choroid tissues have been used to study passive permeability and active transport.
Typically the tissue is located between donor and acceptor compartments in a Ussing type chamber
system (Pitkänen et al. 2005, Steuer et al. 2005, Steuer et al. 2004). Pitkänen et al. used bovine RPE-
choroid tissues to study the effect of lipophilicity and molecular weight on drug permeability in RPE-
choroid (Pitkänen et al. 2005). Asymmetric transport of carboxyfluorescein, sodium fluorescein (organic
anion transporter substrate), rhodamine 123 (substrate of p-gp, MRP1 and BCRP) and verapamil
(substrate of several transporters including p-gp) have been detected in isolated RPE-choroid tissues in
studies by Pitkänen et al. (2005) and Steuer et al. (2005). Recently Kansara and Mitra demonstrated
directional folic acid transport in isolated rabbit RPE-choroid tissue (Kansara and Mitra 2006).
2.4.2 Retinal pigment epithelium cell lines
In vitro cell models of outer BRB include primary cells and continuous cell lines, which can be
immortalized or spontaneously transformed. There are some commonly used continuous cell lines e.g.
ARPE-19, D407, hTERT-RPE, h1RPE-7- and h1RPE-116, which are of human origin, and rat RPE-J.
Generally, primary cells can be sub-cultured only for a few passages, whereas continuous cell lines can
be sub-cultured for several passages. Primary cells may preserve the properties of the original tissue
that may be lost when cells are sub-cultured. Melanosomes are seen usually in the primary cells after
their extraction, but they disappear during the sub-culturing procedure (Kanuga et al. 2002). The cellular
variability of primary cells is higher compared to the continuous cell lines. Continuous cells may have
lost some of important features of the original RPE cells. In contrast, continuous cells are easily obtained
and their supply is almost unlimited.
Primary cells. Human primary cells are commonly used in countries with eyebanks whereas in other
countries, their use is limited by availability. Other commonly used primary RPE cell sources include
bovine,  pig,  rabbit,  rat  (Chang  et  al.  1997,  Hernandez  et  al.  1995,  Maenpaa  et  al.  2002,  Stanzel  et  al.,
2005). Extraction of primary cells is a laborious process. A commercial primary RPE cell line (HRPEpiC
cells) is also available from ScienCell Research Laboratories (CA, USA). Various growth media
supplements and growth matrices have been used with primary RPE cells (Capeáns et al. 2003, Hu and
Bok 2001, Frambach et al. 1990, Castellarin et al. 1998, Maminishkis et al 2006, Singh et al. 2001, Song
and Lui 1990). There are studies demonstrating that the primary cells polarize and form a cell layer with
barrier properties (Hornof et al. 2005). The TER values of fetal cell cultures are generally significantly
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higher than those of adult primary cells. TER values as high as 500 ?*cm2 have been measured from
fetal RPE cells (Hu and Bok 2001, Rajasekaran et al. 2003).
ARPE-19. During last decade, the ARPE-19 cell line has become a most popular continuous cell line in
RPE cell research. Originally the cells were extracted from the eye of an 19-year old male donor and they
spontaneously transformed into continuous cell line with the normal number of chromosomes (Dunn et
al. 1996). RPE specific markers, retinal pigment epithelia specific protein 65 kDa (RPE65) and  cellular
retinal aldehyde binding protein (CRALBP), have been shown to be expressed in the ARPE-19 cell line at
the mRNA and protein level, respectively (Dunn et al. 1996). In long term culture on laminin coated
Transwell  membranes,  ARPE-19  cells  (Fig.  5)  were  shown  to  form  a  polarized  monolayer  with  tight
junctions and the tightness could be further increased by culturing cells in a special media designed for
RPE cells (Frambach et al. 1990). In addition, some cells exhibited apical microvilli and basal infoldings.
The heterogenity of ARPE-19 cells has been reported previously (Luo et al. 2006). Polarized secretion of
fibroblast growth factor 5 and interleukins 6 and 8 have been detected in filter grown ARPE-19 cells
(Dunn et al. 1998, Holtkamp et al. 1998). ARPE-19 cells have been widely used, in studies on oxidative
stress, retinal pathogenesis, signaling pathways as well as in drug and toxicity related studies (Glotin et
al. 2008, Haritoglou et al. 2009, Huhtala et al. 2009, Lara-Castillo et al. 2009, Thurman et el. 2009).
Figure 5. Schematic presentation of the typical ARPE-19 membrane culture. Cells are cultured on
membranes with or without coating. Separation of apical and basal compartments allows transepithelial
studies in passive diffusion, active transport and, in addition, the direction of protein secretion can be
studied using this polarized cell model.
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D407. The spontaneously transformed RPE cell line D407 was shown to have typical features of RPE cells
including cobblestone appearance, binding of POS, expression of CRALBP protein and expression of
cytokeratins typical to RPE (8 and 18) (Davis et al. 1995). The growth potential of these cells is high. This
may be related to the nearly perfect chromosomal trisomy observed in these cells. Unfortunately D407
cells do not polarize in filter culture and they do not synthesize pigment.
hTERT-RPE. hTERT-RPE cell line was immortalized by transfecting human telomerase catalytic subunit
into human RPE cells (Bodnar et al. 1998). These cells have an extended life span with normal
chromosomes and growth behavior (Jiang et al. 1999). Melanization of cells was detected in long-term
serum free cultures (Rambhatla et al. 2002) and CRALBP expression has been detected with antibodies
(Rambhatla et al. 2002). Alge et al studied differences in protein expression between early passage RPE
cells, ARPE-19 and hTERT-RPE, and concluded that a generally similar expression pattern was shared, but
some differences were noted in protein expression related to cytoskeleton remodeling, polarization, cell
survival, migration and proliferation of the cells (Alge et al. 2006). The polarization and barrier
properties of hTERT-RPE cells in membrane culture have not been evaluated.
h1RPE(-7 and -116). hRPE cells have been immortalized by transfecting human adult primary RPE cells
with the SV40 large T antigen (Kanuga et al.  2002).  These cells  have epithelial  morphology with apical
microvilli, but fail to develop TER above 30-40 ?·cm2 in normal culture conditions. This cell line has been
used in only a few studies. Sub-retinal transplantation of hRPE cells in Royal College of Surgeons (RCS)
rats resulted in rescued photoreceptors for 5 months post-crafting (Lund et al. 2001). P-gp expression
was found in these cells, but no activity could be detected (Constable et al. 2006).
RPE-J. The RPE-J cell line was created by infecting primary rat RPE cells with a temperature sensitive
SV40 virus. When grown on Matrigel coated nitrocellulose filters these cells developed TER of ~350
?*cm2 (Nabi et al. 1993). The tight junctions were found mostly basally, occasionally also apically, and it
was shown that these cells have apical microvilli (Nabi et al. 1993). The cells were capable of
phagocytosing latex beads and polarized distribution of viral proteins was observed but they lacked any
Na, K-ATPase polarity.  The neural  cell  adhesion molecule (N-CAM) was found in lateral  borders.  These
cells have been used to study RPE phagocytosis (Feng et al. 2002, Hall et al. 2003, Strick et al. 2009), the
precense of bestrophin (Marmorstein et al. 2000, Marmorstein et al. 2002) and polarity (Bonilha et al.
1999, Marmorstein et al. 1998). However man must recall that this is a rat cell, and species differences
in transport and metabolism may limit its usefulness in ADME studies.
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2.4.3 Cell culture conditions for retinal pigment epithelial cells
The differentiation of the cell line is affected by the growth conditions such as medium composition and
growth substrate. Various culture conditions have been used with RPE cells.
Growth media. A wide variety of media have been used in RPE cultures e.g. Chee's Essential Medium
(CEM) replacement medium has been frequently used, since it was described by Hu and Bok (2001). This
medium contains zinc, copper, magnesium, selenium, hydrocortisone, linoleic acid, insulin, transferring,
L-ascorbic acid, 1% calf serum, bovine retina extract (BRE; 0.5 % v/v) 0.5 % by volume, and several amino
acids. TER values over 800 ?*cm2 have been measured from fetal primary cells grown in this medium
(Hu and Bok, 2001).  Promising results have been also achieved by using a calcium switch, where cells
are first plated in low calcium media and after reaching confluency, they are changed to a media with
normal calcium concentration (Chang et al. 1997, Stanzel et al. 2005, Rak et al. 2006). This method has
been shown to synchronize cadherin expression (Nelson, 2008). A low serum concentration is frequently
used because serum contains a factor that inhibits the formation of tight junctions (Chang et al. 1997).
In primary RPE cell cultures, typical supplements include basic fibroblast growth factor (bFGF) and
bovine retina extract (BRE) (Hu and Bok 2001, Frambach et al. 1990, Castellarin et al. 1998, Song and Lui
1990).  Different other media supplementations as well as different glucose concentrations have been
also tested, but there are no systematic studies nor definitive conclusions about the role of the media
supplements in the properness of cultured RPE derived cells (Engelmann and Valtink 2003, Heimsath et
al. 2006, Karl et al. 2006, Wood et al. 2004).
Growth substrate. It has been shown that the presence of the basement membrane is essential for the
polarization of RPE cells. Since Bruch’s membrane contains laminin and collagens, growth matrices with
these compounds are often used (Chang et al. 1997). Various biological membranes have been used e.g.
amniotic membranes (Stanzel et al. 2005, Capeans et al. 2003, Hamilton et al. 2007, Ohno-Matsui et al.
2005, Ohno-Matsui et al. 2006), donor Bruch’s membranes (Castellarin et al. 1998, Del Priore and Tezel
1998), lens capsule (Hartmann et al. 1999, Nicolini et al. 2000, Singh et al., 2001) and extracellular matrix
derived by cultured corneal epithelial cells (Song and Lui 1990, Campochiaro and Hackett 1993, Wiencke
et al. 2003).
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2.4.4 Differentiation markers of retinal pigment epithelial cells
RPE related genes and protein. The genes and proteins that are found exclusively or at particularly high
quantities in the RPE are often used as differentiation markers of RPE cells. These markers include
RPE65, CRALBP and bestrophin (coded by BEST1 formerly VMD2 gene) (Marmorstein and Kinnick 2007,
Redmond 2009, Saari and Crabb 2005). RPE65 and CRALBP are both involved in the vitamin-A cycle, in
the regeneration of visual pigment (Jin et al. 2005, Moiseyev et al. 2005, Saari et al. 2001). The exact role
of bestrophin is not clear, but some studies suggest that bestrophin plays a role in chloride conductance
and homeostasis of intracellular calcium and pH in RPE cells (Marmorstein et al. 2009, Qu et al. 2006).
Homeodomain containing (OTX2) and microphthalmia-associated (Mitf) transcription factors have
important roles in the regulation of RPE differentiation (Martinez-Morales et al. 2003).  The polarized
expression of some proteins in RPE is known in vivo.  These  have  been  also  used  as  markers  of
differentiation and proper polarization. For example, Na/K-ATPase, ???5 integrin, monocarboxylate
transporter-1 (MCT-1), folate transporter protein (RFT-1), are expressed apically in RPE and basolaterally
enriched proteins include monocarboxylate transporter- 3 (MCT-3), folate receptor FR? and bestrophin
(Gundersen et al. 1991, Marmorstein et al. 2000, Bridges et al. 2002, Finnemann et al. 1997, Philp et al.
1998).
Phagocytosis. Functional  features  typical  of  the   derived  cell  lines  such  as  phagocytosis  in  the  case  of
RPE  cells,  provides  some  indication  about  the  state  of  differentiation.  Phagocytosis  in  RPE  cells  is  a
strictly controlled process involving several proteins. POS phagocytosis is divided into binding and
internalization phases. The receptor tyrosinase kinase c-mer (MerTK) and integrin receptor ???5 have
important  roles  in  POS  binding,  and  MerTK  in  activation  of  intracellular  signaling  cascade  (Feng  et  al.
2002, Finnemann et al. 1997). Macrophage scavenger receptor CD36 and toll like receptor 4 (TLR-4) are
also involved in the phagocytosis of POS (Finnemann and Silverstein 2001, Ryeom et al. 1996, Kindzelskii
et al. 2004).
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3 AIMS OF THE STUDY
The general aim was to evaluate and further develop a filter grown ARPE-19 cell model as an outer
blood-retinal barrier model for use in drug and gene delivery studies.
Specific aims of the study were:
1. To compare passive permeability of ARPE-19 cell model with isolated RPE-choroid tissue
2. To enhance the barrier properties of the cell model by modification of the growth conditions
3. To study the influence of the cell culture conditions on RPE specific gene expression
4. To compare active efflux transport of ARPE-19 cell model with isolated RPE-choroid tissue
5. To investigate the expression and functionality of efflux transporters in the cell model
6. To study interactions of Hsp inhibitors with efflux proteins using ARPE-19 cells
7. To investigate the non-viral gene transfer in polarized non-dividing RPE cells
8. To evaluate the potential role of transporters in the blood-retinal barrier by conducting
literature search.
23
4 MATERIALS AND METHODS
4.1  Cell culture
4.1.1 Cell lines
Two continuous (ARPE-19 and D407) and two primary RPE cell lines (hRPEpiC and bRPE) were used (I-
IV). Caco2 and transduced MDCKII and HEK293 cell lines were used as positive controls in efflux protein
studies (II). Description, source and references of cell lines are summarized in table 3. The cells were
cultured as described in the original publications (I-IV).
Table 3. Cell lines used in the studies I-IV
Cell lines Description Source References
ARPE-19 human secondary RPE cells ATCC/CRL-2302 and Dunn et al. 1996
provided by Dr L. Hjelmelanda
D407 human secondary RPE cells provided by  Dr R. Huntb Davis et al. 1995
hRPEpiC human primary RPE cells ScienCell Research Laboratories www.sciencellonline.com
bRPE bovine primary RPE cells extracted by ourselves Bejjani et al., 2005)
Caco2 human colorectal adenocarcinoma cells ATCC/HTB-37 Jumarie et al. 1991
Efflux protein expressing cell linesc
MDCKII-MDR1 Madin-Darby Canine Kidney Cells Netherlands Cancer Institute Bakos et al. 1998
MDCKII-MRP1 Madin-Darby Canine Kidney Cells Netherlands Cancer Institute  Bakos et al. 1998
MDCKII-MRP2 Madin-Darby Canine Kidney Cells Netherlands Cancer Institute Evers et al. 1998
MDCKII-MRP3 Madin-Darby Canine Kidney Cells Netherlands Cancer Institute Kool et al. 1999)
MDCKII-MRP5 Madin-Darby Canine Kidney Cells Netherlands Cancer Institute Wijnholds et al. 2000
HEK293-MRP4 Human Embryonic Kidney Cell Line Netherlands Cancer Institute Wielinga et al. 2002
aUniversity of California, Davis, CA, USA  bUniversity of South Carolina, Columbia, SC, USA ckindly provided by Dr P.Borst
4.1.2 Filter culturing of ARPE-19 cells (I, II, IV)
The basic filter-culture protocol for ARPE-19 described by original authors (Dunn et al. 1996) was used
with minor modifications.  Dunn et al (2006) used polycarbonate Transwell filters of 6.5 mm diameter,
but we used polycarbonate filters of 24 mm diameter (I, II and IV). The cell growth area was increased
from 0.33 cm2 to 4.7 cm2. The filters were coated with laminin and the cells wree seeded at a density of
1.6x106 cell/cm2. Filters without coating and collagen coated polyester Transwell filters were tested in
preliminary experiments. The basic filter media consisted of DMEM-F12 (1:1) supplemented with 10 %
FBS, 2 mM glutamine, 100 U/ml penicillin and 100 U/ml streptomycin.  Different supplements were
added to basic filter media in order to improve the barrier properties of ARPE-19 cell monolayer (Table
4). Most of the supplements were commercially available, but BRE and POS were extracted as previously
described (Frambach et al. 1990, Molday et al. 1987). Fresh media with supplements were added to
both apical and basolateral compartments twice a week with the media change. POS were added only to
the apical compartment, since in vivo POS  are  located  only  on  the  apical  side  of  RPE  cells.  The
supplements were tested separately and in addition, media containing BRE, bFGF and taurine in
combination (medium III) was tested. ATRA, sodium pyruvate, taurine, bFGF, BRE, ROS and medium III
were chosen for further testing based on the first results with TER measurements. FBS from two
different suppliers was also tested.
Table 4. Tested media supplements and rationales
Supplement conc. Rationale References
dexamethasone  10 nM promotes formation of tight junctions Underwood et al. 1999
insulin    1 µg/ml integrin expression, viability of RPE cells Uebersax et al. 2000
EGF 10 ng/ ml Mitogen, modulates ion transport in diff. RPE Arrindell et al. 1992
bFGF 10 ng/ ml promotes proliferation, RPE cell morphology, Kaven et al 2000
viability, integrin receptor expression Spraul et al. 2004
vitamin-C  40 µg/ml improves cell growth Rowe et al. 1977
ATRA  25 nM promotes epithelial cell type, growth control Campochiaro et al. 1991
forskolin  10 µM Increase in  intracellular cyclic AMP, Insel and Ostrom 2003
IBMX 100 µM Increase in  intracellular cyclic AMP Njie-Mbye et al. 2009
sodium butyrate      1 M modulates gene expression, differentiation Cuisset et al. 1997
sodium pyruvate      1 nM participates cell energy metabolism Wood et al. 2005
taurine    10 mM most abundant and essential amino acid in retina  El-Sherbeny et al. 2004
BRE      1 % unknown composition, promotes differentiation Frambach et al. 1990
POS 120x106  ingested by RPE daily in vivo Molday et al. 1987
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4.1.3 Transepithelial resistance measurements (I, II, IV)
The development of tight junctions was followed by TER-measurements by Endohm chamber (World
Precision Instruments) (I, II, IV). The average resistance of laminin coated blank filter was 8 ?cm2. The
resistance of blank filter was subtracted from the resistance of the filter with cells to obtain the
resistance of the cell layer.
4.1.4 Electron microscopy
Electron microscopy was used to study morphology of ARPE-19 monolayers in basic filter medium (V)
and in media supplemented with bFGF and BRE. The preparation of samples is explained in detail in
original publication IV. Morphology of isolated POS was also studied by electron microscopy. The
specimens were inspected with transmission electron microscopy (JEM 1200 EX).
4.1.5 Photoreceptor outer segment phagocytosis
POS were isolated from bovine neural retina with sucrose density gradient according to the procedure
of Molday et al. ( 1987). POS were labeled with FITC at room temperature for one hour. FITC-POS were
washed four times with 1 x PBS and re-suspended to ARPE-19 culture medium.  After counting, FITC-POS
were  fed  to  ARPE-19  cells  in  6-  or  24-  well  plates.   Cell  uptake  of  FITC-POS  was  measured  with  flow
cytometry (FACScan, Becton Dickinson) using an argon ion laser (488 nm) as the excitation source and
fluorescence was detected at 670 nm.
4.2 Expression studies
4.2.1 Real time quantitative polymerase chain reaction (I, II)
Expression of efflux proteins (p-gp, MRP1-6, BCRP) and RPE cell related proteins (RPE65, bestrophin,
CRALBP, tyrosinase, TRP1, MITF-A (microphthalmia-associated transcription factor) and OTX2
(homeodomain-containing transcription factor) was studied at the RNA level by quantitative real time
PCR (RT-qPCR).
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 The total RNA was extracted using TRI-Reagent®, DNAse treated, quantified using RiboGreen
quantification assay and reverse transcribed (II, III). The samples were diluted and divided into small
aliquots enough for one PCR run in order to avoid repeated thaw and freeze cycles. A total of 40 ng of
each cDNA was amplified using ABI Prism 7000 system using either FAM-labeled Assay on Demand
TaqMan® Gene Expression Assays (Table 5) or custom made primers and probes (Table 6).
Table 5. Taqman gene expression assays
gene primer/probe set gene  primer/probe set
RPE65 Hs00165642_m1 MRP1 Hs00219905_m1
CRALBP Hs00165632_m1 MRP3 Hs00358656_m1
VMD2 Hs00188249_m1 MRP4 Hs00195260_m1
MITF-A Hs01115553_m1 MRP5 Hs00981071_m1
OTX-2 Hs00222238_m1 MRP6 Hs00184566_m1
Table 6. Custom made primers and probes for q RT-PCR
gene forward primer reverse primer label
Tyrosinase* agcaccccacaaatcctaacttac atggctgttgtactcctccaatc SYBR green dye
TRP1* agccttctttctcccttccttactg gtgcaggaggacaaaaataggatca SYBR green dye
gene forward primer reverse primer Taqman probe
MDR1** gatcacaagcccaagacaga caacaaaataaggccattcagt ttagtaccaaagaggctctggatgaaagtatacc
MRP2** acatctgccattcgacatga ccaggttcacatctcggact caattttgacaaagccatgcagttttctga
BCRP** caggactcaatgcaacaggaaa agatcgatgccctgctttacc ccttgtaactatgcaacatgtactggcgaagaa
*Primers designed by using Primer express (Applied Biosystems), OLIGO (Molecular Biology Insights, Inc.) and BLAST programs.
**Korjamo et al. 2005
Two approaches were used to analyze gene expression results: Relative gene expression and absolute
quantitative approach (Bustin 2002). The relative gene expression allows comparison between one gene
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in different conditions, but does not allow comparison of expression levels between different genes. The
results were calculated separately from each plate, relative to ARPE-19 cells grown either in flasks or on
filters (I).  The absolute gene expression was calculated with standard curves that were run each time
with the samples.  The standard curves were generated using restriction fragments of plasmids with the
same gene sequences (II). In this case, absolute comparison between different genes is possible.
4.2.2 Western blotting (II)
Western blotting was used to study MRP1, MRP2, MRP4, MRP5 and BCRP expression at protein levels in
different RPE cells. The information about the antibodies is listed in table 7. The western blotting was
performed as described in the publication (II).
Table 7. Antibodies, dilution rations and positive controls for western blot studies
Efflux
protein
primary antibody secondary antibody positive control
cell line
MRP1 ab3368 (MRPr1)  1:5 000 Rat       1:10 000 MDCKII-MRP1
MRP2 ab3373 (M2 III-6)  1:4 000 Mouse 1:8 000 MDCKII-MRP2
MRP4 ab15602 (M4I-10) 1:5 000 Rat      1:10 000 HEK293-MRP4
MRP5 ab3377 (M5I-1) 1:1 000 Rat 1: 1 000 MDCKII-MRP5
BCRP ab3380 (BXP-21),
1:2000
Mouse 1:2 000 Caco2
4.3  Permeability experiments (I)
Permeability experiments were used to study both passive and active drug transport across ARPE-19
monolayers  (I). The permeant molecules included 6-carboxyfluorecein, sodium fluorescein, rhodamin
123, betaxolol, digoxin, cyclosporin A and FITC-dextran 40 kDa. Molecular properties (molecular weight,
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logD), donor concentrations and possible transporters of the molecules are shown in table 1 (I). The
permeant molecules were added to either the apical or basolateral compartments (donor compartment)
and samples were taken from the receiver compartment at 15 min intervals up to three hours.
Fluorescence of 6-carboxyfluorescein, sodium fluorescein, rhodamine 123 and FITC-dextran 40 kDa
samples were measured using Victor 1420 Multilabel Counter. Betaxolol concentrations were measured
by HPLC with combined ultraviolet and fluorescence detection as described previously by Ranta et al.
(2002). Radioactivity of tritium labelled cyclosporin A and digoxin was detected with liquid scintillation
counter. Apparent permeability was calculated according to equation:
Papp = J/(A*C0),
 where A is  the surface area of the filter,  C0 the drug concentration in the donor chamber at time zero
and J is flux of the permeant molecule from donor to receiver compartment.
4.4  Cellular uptake studies (II, III)
4.4.1  Calcein-AM assay (II, III)
Calcein-AM assay was used to test efflux protein activity of ARPE-19 and primary bovine RPE cells (II)
and to assess interactions between Hsp90 inhibitors geldanamycin and radicicol with efflux proteins (III).
Calcein acetoxymethyl ester (calcein-AM) is a cell permeable compound that is metabolized by
intracellular esterases to cell impermeable calcein (Fig. 6). Calcein-AM is a substrate of p-gp and MRP1
efflux proteins and calcein is a substrate of MRP1 and MRP2 (Essodaigui et al. 1998, Evers et al. 2000)
(Fig. 6). Inhibition of efflux transport by test drugs causes calcein accumulation and an increase in the
intracellular fluorescence (Eneroth et al. 2001). The assay was conducted as described earlier (Eneroth
et al. 2001, Vellonen et al. 2004). In brief, ARPE-19 cells were cultured for four days prior to the
experiment on 96-well plates. The cells were exposed to inhibitors for 15 min before calcein-AM was
added for 20 min. The fluorescence from the cells was measured immediately after the experiment
using Victor 1420 Multilabel counter.
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Figure 6.  The schematic presentation of calcein-AM assay. Cell permeable calcein-AM is metabolized by
esterases to calcein inside the cell. Calcein and calcein-AM are substrates of efflux proteins. Inhibitors of
MRP1, MRP2 and MDR1 efflux proteins are shown in the picture. The efflux inhibition can be detected
as an increased cellular fluorescence.
4.4.2 CDCFDA/CDCF assay (III)
CDCFDA/CDCF assay was used to assess MRP5 activity (III).  The method is similar to Calcein-AM assay:
CDCFDA is a cell permeable compound that is cleaved inside the cell by esterases to relatively the
impermeant and fluorescent CDCF. CDCF is a substrate of MRP2, MRP3 or MRP5 (McAleer et al. 1999,
Tian et al. 2004, Zamek-Gliszczynski et al. 2003). MRP transport can be inhibited by probenecid, which is
a non-specific inhibitor of organic anion transporters. MDCKII cell lines expressing MRP proteins (table 3)
and ARPE-19 cells were used for the assay. The cells were cultured for four days prior to the
experiments on 96-well plates. The cells were exposed to CDCFDA for 20 min and after two washes the
probenecid containing buffer or the plain buffer was added to the cells. The samples were collected
from the buffer at 30 and 90 min. The fluorescence was measured with a Victor 1420 Multilabel counter.
4.5  Non-viral gene delivery (IV)
Polarized ARPE-19 cells were used to study non-viral gene delivery and uptake of non-viral gene delivery
complexes. The cells were cultured for four weeks prior to the experiments. Polarization was confirmed
with TER measurements before and after the experiments. Non-viral gene transfer was accomplished
with cationic carriers that form condensed nanoparticulates with plasmid DNA.
C-AM CalceinC-AM
MDR1
MRP1
MRP2
MK 571
Verapamil
Cyclosporin A
Fluorecence
MK 571
Verapamil
Progesterone Cyclosporin A
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4.5.1 Transfections with non-viral DNA/carrier complexes (IV)
Plasmid (pCMV-SEAP2) encoding SEAP as a reporter gene under control of CMV promoter was
constructed by inserting the CMV enhancer/promoter fragment from p-CL-neo vector to pSEAP2-Basic
vector  (Clontech).   Cationic  polymer  carriers  PEI  25  kDa  and  lipids  DHP-12,  DOTAP  and  DOTAP/DOPE
were prepared as described earlier (Boussif et al. 1995, Hyvonen et al. 2000, Ruponen et al. 1999).
Charge ratios (carrier:DNA) were optimised in preliminary experiments. Complexes of pCMV-SEAP2
plasmid  with  the  carriers  were  allowed  to  form  for  20  min  before  adding  them  to  the  apical
compartment of polarized ARPE-19 cells. After 5 hours, the complexes were washed off and medium
samples from apical and basolateral compartments were collected at different time points. The SEAP
concentration was measured using Great EscAPE SEAP Chemiluminescence Detection kit (Clontech).
4.5.2 Cellular uptake of non-viral DNA/carrier complexes (IV)
For cellular uptake studies pCMV-SEAP2 plasmid was labelled with fluorescent EMA (Zabner et al. 1995).
Transfections with EMA-pCMV-SEAP2 complexed with PEI, DOTAP/DOPE and DOTAP/DOPE/PS were
done as described above. The cells were washed with 1 M sodium chloride, detached from filter
membranes and fixed with paraformaldehyde for flow cytometric analysis. The results from 10 000 cells
were  expressed  as  a  percentage  of  positive  cells  and  the  fluorescence  intensity  of  the  cells  was  also
monitored.
4.6  Statistical analyses
All  statistical  analyses were performed using SigmaStat 3.5 software (SSPS Inc.,  Chicago, IL,  USA).  Pair-
wise comparisons were done using Student’s t-test and Mann-Whitney U-test (when a normal
distribution was not present) (I,II, IV). P<0.05 was considered as a significant difference. Kruskal-Wallis
analysis was used to compare multiple experimental groups. When the difference was significant
(p<0.05), the comparisons versus control group (calcein-AM assay) or pair-wise comparisons
(CDCFDA/CDCF-assay) were conducted with the Dunn's test (II).
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5 RESULTS
5.1 Characterization of ARPE-19 cell culture model
5.1.1 Resistance
In two weeks, the TER values reached a plateau, typically between 80 and 100 ? x cm2 and remained at
this level for as long as several months (I, II, IV).  Higher  TER  values,  even  above  150  ? x  cm2, were
detected when either BRE or bFGF was added to the culture media (I Fig. 2). In other tested media the
resistances were similar or lower than in basic filter medium (I Fig. 2).
5.1.2 Morphology
In the basic filter culture medium, ARPE-19 cells on Transwell membranes grew mainly as a monolayer
(IV Fig 2A), but some cell overlapping was observed. Heterogeneity was found in the existence of apical
microvillae between cells. Basal infoldings were frequently observed.  Cell-to-cell junctions that
resembled desmosomes, tight junctions and zonula adherens were found between the cells (IV Fig. 2B).
in contrast, multilayering of ARPE-19 cells was found when either BRE or bFGF was present in the culture
media (pictures not shown).
5.1.3 Expression of RPE related genes
ARPE-19 cells expressed all analysed RPE related genes: RPE65, CRALBP, VMD2, tyrosinase,TRP1 and
transcription factors (OTX-2, MITF-A), which are responsible for regulating several RPE cell functions (I).
Expression levels of RPE65, VMD2, CRALBP, TRP1 and tyrosinase were increased 37, 2, 13, 1860 and 550-
fold, respectively, when the cells were cultured for prolonged periods on filter membranes (I Fig. 3A).
The influence of the culture media composition was much smaller (I and Fig. 7).
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Figure 7. Comparison of RPE65, VMD2, CRALBP, TRP1 and tyrosinase mRNA expression between filter
cultured ARPE-19 cells in various media. The results are from two independent cultures each performed
in triplicates and presented as the mean normalized expression±SD relative to filter cultured cells in
basic filter culture media, which is set to one.
5.1.4 Passive permeability
Passive permeability of ARPE-19 monolayer in basic filter culture media was 3-17 times higher than the
permeability of the isolated bovine RPE-choroid tissue (I Fig. 1). Clear differences in the permeation in
ARPE-19 cell model were found among compounds with different molecular sizes and lipophilicities.
Permeability values of 6-CF, FD-40 kDa and betaxolol were 7.2, 0.8 and 33.3*10-6 cm/s respectively.
Lower passive permeability of 6-carboxyfluorescein (3.5 and 4.3*10-6 cm/s) was found when BRE or
bFGF or was added to the culture medium (I Fig. 2).
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5.1.5 Photoreceptor outersegment phagocytosis
Typical morphological structures of isolated POS were observed with transmission electronic microscopy
(Fig. 8). FACS analysis revealed that ARPE-19 cells ingested FITC-POS by concentration dependent
manner and the results were changed by lowering the temperature from 37 oC to 4 oC (Fig. 9) sindicative
of an energy dependent process.
Figure 8: POS isolated from bovine neural retina using a sucrose density gradient. Scale bar 2 µm (left)
and 1 µm (right)
Figure 9: POS ingestion by ARPE-19 cells at +4 and +37 degrees. Cell confluency of 85-90% was reached
prior to the experiments. Control: cell culture media. Results are expressed as mean ±sd (n=4).
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5.2 Efflux proteins in RPE cell lines
5.2.1 Expression at the messenger RNA level
MRP1, MRP4 and MRP5 transcripts were expressed in all the RPE cell lines (ARPE-19, D407 and HRPEpiC)
(II  Fig  1, Fig. 10). MRP2 and BCRP transcripts were present only in D407 cell line (II  Fig  1). MRP3 was
expressed at a much higher level in D407 compared to ARPE-19 and HRPEpiC cell lines (II Fig 1). MDR1
mRNA was expressed in D407 and variably in hRPEpiC cells (II  Fig  1). In ARPE-19 cells filter culturing
enhanced MRP1, MRP4 and MRP5 expression, but the same efflux proteins were expressed in different
culture culture conditions (II Fig.2, Fig 10).
Figure 10. Transcript expression levels of efflux proteins in human RPE cell lines. Data are expressed as
transcript copy number/40 ng cDNA from 2 to 3 independent cell cultures measured in triplicate. The
data are expressed as the mean±SD.
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5.2.2 Expression at the protein level
MRP1, MRP4 and MRP5 were expressed also at the protein level in the studied RPE cell lines (II Fig. 3). In
addition, MRP1 and MRP4 were also detected in the bRPE (II Fig. 3). Again MRP2 and BCRP were present
only in the D407 cell line (II Fig.4)
5.2.3 Bi-directional permeability
Similar directionality of transport was seen in ARPE-19 cells and isolated bovine RPE-choroid tissue (I
Table  2). However, there were quantitative differences between ARPE-19 cells and isolated tissue.
AB/BA (apical to basolateral permeability/basolateral to apical permeability) ratios of sodium fluorescein
and rhodamine 123 were 1.5 and 1.7 in ARPE-19 cell model and 8.3 and 5.0 in the bovine RPE-choroid,
respectively. The AB/BA ratio of digoxin was about the same ( ~1.2) in the cell model and in the RPE-
choroid tissue.  The directionality in carboxyfluorescein transport was seen in isolated bovine RPE-
choroid tissue (AB/BA~2.4) but not in ARPE-19 monolayers (I Table 2).
5.2.3 Calcein-AM assay
In the calcein-AM assay, cellular fluorescence of ARPE-19 cells was increased over 100% with all tested
inhibitors (cyclosporin A, progesterone, verapamil, MK571) (II Fig. 5). In the bRPE cells, progesterone,
verapamil and MK571 resulted in >100% increase in the cellular fluorescence, whereas with cyclosporin
A, the increase was around 40% (II Fig. 5).
The interaction of efflux proteins with two Hsp inhibitors, geldanamycin and radicicol, was evaluated
using calcein-AM assay (III). Increased cellular fluorescence was detected when the cells were exposed
to radicicol (either 1 µM or 5 µM) pointing to an interaction with the efflux proteins (III Fig. 6).
5.2.4 CDCFDA/CDCF assay
Probenecid inhibited CDCF efflux of ARPE-19 cells indicative of MRP5 activity (II Fig.  6).  An  effect  of
increasing concentration of probenecid was seen at 90 min, but not at 30 min.
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5.3  Non-viral gene transfer
5.3.1 Marker gene expression in ARPE-19 cell culture model
Prolonged  expression  of  SEAP  for  69  days  was  seen  when  the  filter  grown  ARPE-19  cells  were
transfected with DOTAP/DOPE/PS complexes (IV Fig. 3 A and B). In the experiments with DOTAP/DOPE
complexes, SEAP expression lasted for 55 days. PEI, DOTAP and DHP-12 complexes resulted in the SEAP
expression for 14 days or less. The highest expression peak was detected when DOTAP/DOPE/PS was
used as a carrier (IV  Fig.  3  A  and B).  The total  amount of secreted SEAP was 49 and 143 µg/106 cells,
with DOTAP/DOPE/PS and DOTAP/DOPE complexes, respectively, whereas other complexes yielded less
than 5 µg/106 cells  (IV Table 1). In addition, directionality was observed in the SEAP expression. With
DOTAP/DOPE/PS and DOTAP/DOPE complexes, 1.5-fold higher secretion of SEAP was detected on the
basolateral side, whereas with PEI/pDNA complexes 1.4 times greater secretion of SEAP was measured
on the apical side (IV Table 1).
5.3.2 Cellular uptake of non-viral complexes
The highest cellular uptake was seen when polarized ARPE-19 cells were transfected with PEI/pDNA
complexes (IV Fig. 4). Including PS in DOTAP/DOPE/complexes resulted in higher uptake of lipoplexes (IV
Fig. 4)
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6 DISCUSSION
6.1 ARPE-19 filter culture as a model for drug delivery studies
RPE is a polarized epithelium, which is a key feature in its role as drug delivery barrier. An optimal drug
screening cell model for outer BRB should mimic the normal in vivo tissue, and it should be relatively
easy  to  handle,  readily  available  and  suitable  for  large  scale  screening.  The  ARPE-19  cells  line  is
commercially available, the cells can be easily expanded and it has retained many important features of
the  RPE  cells.  Importantly,  when  grown  on  a  filter,  it  forms  a  polarized  monolayer,  which  can  be
maintained for long periods, even for over a year. Very good barrier properties have been achieved with
primary cells, but they are too laborious for screening purposes (Hu and Bok 2000, Maminishkis et al.
2006, Sonoda et al.2009).  Thus,  the ARPE-19 cell  line is  a candidate model for drug screening in outer
BRB, but its drug permeation and transport properties have not been adequately characterized. In
addition, it is currently widely used in retinal research.
The barrier properties of ARPE-19 cell filter culture model were studied by TER measurements and
permeability studies (I, II, IV). Another commonly used method to study barrier properties is to study
the expression of cell to cell junctions associated proteins by antibody labelling, with the most
commonly used proteins being zonula occludens protein 1 (ZO-1) and occludin. Unfortunately it has
been shown that these proteins can be present without the development of tight junctions (Luo et al.
2006). In addition, expression of ZO-1 and occluding has been previously demonstrated in ARPE-19 filter
culture (Geisen et al. 2006, Nevala et al. 2008). Taking these facts into account, we chose to study the
functionality of the cell to cell junctions by performing TER measurements and permeability studies.
The TER values of ARPE-19 cells on filter were generally between 80-100 ?*cm2. These are clearly higher
than most of reported TER values (typically between 30 and 40 ?*cm2) of ARPE-19 cells cultured on
filters  without modification of culture medium or growth membrane (Dunn et al. 1996, Luo et al. 2006,
Holtkamp et  al.  1998,  Geisen  et  al.  2006).  Abe  et  al  (2003)  reported  TER  values  similar  to  our  values,
about 80 ?*cm2. The main difference between the previous studies and this present one was that we
used filters with a larger growth area (4.7 cm2) whereas in most studies, smaller filters (growth area 0.33
cm2) have been used. It is also well known that cell lines can change with time and this may account for
some of the observed lab to lab differences. In this study, ARPE-19 cells from two different sources were
used and generally the cells behaved in a reproducible manner.
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ARPE-19 cells grown on the filter in the standard growth medium formed a more permeable barrier to
test compounds than isolated RPE-choroid tissue (I). However, the ARPE-19 cell model was able to
detect the difference between the permeant molecules based on their size and lipophilicity (I).  On the
other hand, some established drug test cell models (like Caco2 and many brain endothelial cell models)
deviate remarkably from their in vivo counterparts (small intestine, blood-brain barrier) (Artursson et al.
2001, Deli et al. 2005). Unfortunately the tested culture media supplements did not result in any better
barrier properties without disturbing the morphological characteristics of the RPE cells.
The culture media composition can have substantial effects on the cell phenotype. When the culture
medium was supplemented with bFGF or BRE, there was multilayering of ARPE-19 cells on the filters.
The effect of these compounds were tested, since they have been shown to enhance the differentiation
of RPE cells in vitro and have been frequently used with primary RPE cells (Hu and Bok 2001, Song and
Lui 1990, Campochiaro and Hackett 1993). However, it is possible that different concentrations of bFGF
and BRE could have influenced the results. The exact composition of BRE is unknown and its
composition is likely to differ between extractions. Similarly, the composition of FBS can also differ
between different manufacturers and batches. In general, cells cultured in media containing
components extracted from other species are not ideal for human use.
The effect of culture conditions on RPE related gene expression was studied (I). All RPE related genes
were expressed in ARPE-19 cells and all RPE related genes except Best1/VMD2 were up-regulated in
filter cultures compared to the cells grown in flasks. To some extent this up-regulation can be explained
as a consequence of the prolonged culture time. Our results are in agreement with Alizadeh et al. (2001)
and Pratt et al. (2008) who reported Increasing expression of CRALBP and RPE65 transcripts,
respectively, in prolonged culture of ARPE-19 cells.  However, it is possible that also filter culturing itself
may enhance the gene expression of RPE related genes. Interestingly, differences in gene expression
levels were much smaller between different growth media compositions in ARPE-19 filter cultures (I).
To conclude, our results suggest that prolonged culture on filters enhances RPE related gene expression.
Pigmentation is a landmark feature of RPE cells in vivo, and this feature also affects drug delivery.
Ophthalmic drugs, particularly lipophilic compounds, may bind to melanin. For example, pilocarpine,
timolol  and  atropine  are  known  to  bind  to  melanin  (Atlasik  et  al.  1980,  Nagata  et  al.  1993).  Melanin
binding of the drug may lead to its accumulation in the tissue and slow release from the bound depot,
which prolongs the drug’s action. On the other hand, melanin binding may decrease the access of the
drug to its site of action and reduce the peak event. These phenomena have been shown in association
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of pilocarpine binding to the pigment in iris and ciliary body (Urtti et al. 1984). In the present study, we
detected tyrosinase, TRP1, MITF-A and OTX2, which are important proteins in melanization, from ARPE-
19 cells at the mRNA level (I). However, we could not detect melanization in normal cell culture of ARPE-
19 cells, not even with prolonged culture. The lack of pigmentation is an obvious limitation that affects
the intracellular drug accumulation in some cases.
Phagocytosis is one of the most important features of RPE cells. In vivo malfunctioning of phagocytosis
leads to visual impairment as seen in Royal College of Surgeons rats, who lack functional MerTK protein
(D’Cruz et al. 2000, Nandrot et a. 2000). We have detected the MerTK transcript (data not shown) as
well as TLR-4 transcript (Paimela et al. 2007), and ???5 integrin (data not shown), all important proteins
related to POS phagocytosis, in flask cultured ARPE-19 cells. We also observed that ARPE-19 cells
phagocytozed labeled POS in a temperature dependent manner (Fig.9), confirming the previous studies
that ARPE-19 cells have retained this important task of the RPE cells in vivo (Finnemann et al. 1997).
It is known that cell division affects the access of DNA into the nucleus, and therefore the filter grown
ARPE-19 model is probably more relevant than dividing ARPE-19 cells in gene delivery experiments
(Ludtke et al. 2002). The filter culture model with secreted marker gene, SEAP, allowed generation of an
expression vs time curve. PEI-DNA complexes have been previously shown to be efficient in vitro in
transfecting dividing cells (Boussif et al. 1995, Toropainen et al. 2007).  In this study, lipoplexes were
shown to be more efficient than PEI-polyplexes in ARPE-19 filter culture system (IV).  PEI-polyplexes
resulted in short-term SEAP secretion to the medium whereas SEAP expression continued for 2 months
after a single DNA lipoplex administration (IV). Likewise, Toropainen et al. (2007) showed that the filter
grown corneal epithelial cells predict in vivo gene transfer much more reliably than dividing corneal
epithelial cells. The mechanisms of DNA complex internalization and intracellular trafficing of plasmid
DNA in ARPE-19 cells are not fully understood.
6.2 Membrane transporters in retinal pigment epithelium
ABC efflux transporters. Efflux proteins have broad substrate specificity and they affect
pharmacokinetics of a large number of drugs (Cascorbi 2006, Dobson and Kell 2008, Maeda and
Sugiyama 2008, Mizuno et al. 2003). Therefore, expression of these proteins is a potentially important
factor in the RPE related drug delivery.  The substrate and inhibitor specificities of ABC efflux proteins
overlap, complicating interpretation of the results.  In most cases, the functional studies with probe
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molecules can only suggest a set of possible transporters. For example, rhodamine 123, a commonly
used substrate to study p-gp function, is also a substrate of MRP1 and BCRP (Doyle et al. 1998,
Minderman et al. 1996, Twentyman et al. 1994, Zaman et al. 1994).
In this study, efflux protein expression was compared in various RPE cell lines. Previously it was reported
by Constable et al (2006) that p-gp was expressed and active only in D407 cell line, whereas ARPE-19
cells lacked the p-gp expression and activity. The present qPCR results are in line with this observation,
no p-gp expression was found in ARPE-19, but was consistently found in D407 cells and variably in
hRPEpiC cells batches (I). In general, there is no consensus in the literature about p-gp expression in the
RPE (Esser et al. 1998, Kennedy and Mangini 2002, Steuer et al. 2005). The conflicting results may be
explained by different sensitivities of detection methods and also by inducibility of p-gp expression and
polymorphism. It is clear that P-gp expression and activity in RPE require further clarification.
MRP1 has been detected in RPE in several studies (Steuer et al. 2005, Aukunuru et al. 2001, Pelis et al.
2009, Zhang et al. 2008). In this study, MRP1 was detected in all studied cells lines and in normal bovine
RPE cells (II). This is the first report of MRP1 expression in bovine RPE. Several studies have suggested
that MRP1 transport takes place from the neural retina to the choroid direction. Active transport of
fluorescein from retina to choroid has been known for decades, but the transporter responsible is not
known (Barza  et  al.  1983,  Cunha-Vaz  and  Maurice  1967),  though it  is  likely  that   MRP1 plays  a  major
role. Calcein-AM studies and bi-directional studies confirmed the activity of MRP1 in ARPE-19 cells (I, II).
Inhibition of efflux activity was detected with the Hsp inhibitor radicicol (III). Since neither p-gp nor
MRP2 are expressed in ARPE-19 cells, these results indicate that radicicol is interacting with MRP1.
MRP4 and MRP5 were expressed in ARPE-19, D407 and HRPEpiC cells at the mRNA and protein levels
(II). MRP4 protein was also detected from bovine RPE, but MRP5 protein was not found (II). This may be
due to an inability of the MRP5 primary antibody to bind to bovine tissue. This was the first study to
report MRP4 expression in the RPE. A finding was confirmed recently i.e. MRP4 expression was detected
by western blot in the human eye (Pelis et al. 2009). Up-regulated expression of the MRP4 and MRP5
proteins was detected in ARPE-19 filter culture, whereas the level of MRP1 expression was quite
constant under different culture conditions (II Fig 2). In general, it is possible that cell culture conditions
alter the expression of some efflux proteins.
Two papers have been published during 2008-2009 on the expression of efflux transporters in the
human eye (Pelis et al. 2009, Zhang et al. 2008). Zhang et al. studied mRNA expression of various
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transporters by quantitative RT-PCR and Pelis et al. used western blot to detect protein expression.
Zhang et al. had inner and outer BRB in one specimen (retina/choroid) whereas Pelis et al. studied retina
(including  inner  BRB)  and  RPE  (outer  BRB)  separately.  MRP1  mRNA  was  highly  expressed  in
retina/choroid and MRP1 protein was clearly expressed in RPE. MRP2 was also detected in both studies.
MRP3 mRNA was expressed at a low level (not studied at the protein level) whereas MRP4 protein was
expressed in the RPE (not studied at the mRNA level). MRP5 and MRP6 were not studied in either study.
A faint band was seen in western blot in RPE with P-gp antibody and mdr1 mRNA was expressed at a low
level. BCRP was detected at both the RNA and protein levels. These results suggest that also MRP2 and
BCRP are expressed in the human RPE. In the present studies, these efflux proteins were detected only
in D407 cells (II Figs. 1 and  4). Interestingly, these efflux proteins were not detectable from bovine RPE,
but one cannot be sure if the primary antibodies are able to detect the bovine efflux protein.
 Similar efflux protein expression has been found in other barrier membranes. The expression of P-gp,
MRP1, MRP5 and BCRP has been described both in BBB and placenta (Nies et al. 2004, Zhang et al. 2004,
Young et al. 2003). MRP4 have been also detected in the BBB and with respect to MRP2 and MRP3
expression,  the  results  are  controversial  (Berezowski  et  al.  2004,  Nies  et  al.  2004,  Zhang  et  al.  2004,
Young et al. 2003). MRP2 has been found in placenta, whereas expression of MRP3 and MRP4 are
uncertain (Pascolo et al. 2003, St-Pierre et al. 2000).
MRP4 and MRP5 may affect the distribution of nucleoside analogue drugs by effluxing the intracellularly
formed respective nucleoside monophosphate metabolites from the cells. Some drugs used to treat
vitreal and retinal diseases have been shown to interact with MRP4 or MRP5, these include zidovudine,
ganciclovir and 5'-fluorouracil (Adachi et al, 2002, Jorajuria et al. 2004, Pratt et al. 2005). Furthermore, it
has been shown that vincristine, etoposide and teniposide, which are used to treat retinoblastoma,
interact with MRP4 (vincristine) and MRP5 (etoposide and teniposide), however the resistance factor
attributable to the presence of the transporter is low (Wijnholds et al. 2000, Norris et al. 2005). In
addition MRP4 has an ability to transport prostaglandins and it participates in prostaglandin
homeostasis in the BBB (Kis et al. 2006). Active efflux transport for prostaglandins is known to be
present also in the eye, where prostaglandins perform several important functions (Bito 1973). Synthetic
prostaglandin analogues are used as therapeutics in glaucoma. The clinical significance of MRP4 and
MRP5 in drug resistance is unknown.
In summary this study in conjunction with previous reports provides consistent evidence that MRP1,
MRP4 and MRP5 are expressed in RPE, but MRP6 is not expressed, and MRP3 is expressed at only a low
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level. Details of p-gp expression are unclear. Recent studies have suggested that also MRP2 and BCRP
can be expressed in the outer BRB, but these preliminary findings need to be confirmed.
Drug delivery related influx transporters. In the literature review (V) 19 SLC membrane transporters
that may be involved in drug influx were detected in RPE. Subsequently 7 possible new drug related
transporters have been found in RPE. Twenty of these 26 membrane transporters belonging to 10
different SLC subfamilies have been detected in ARPE-19 cell line (Table 8). Some of these transporters
have polarized location in confluent or polarized ARPE-19 cell cultures (Table 8).  The uptake of
adenosine, brimodine, cystine, folate, glutamate, lactate, L-phenylalanine, methylphenyl pyridinium,
nicotinate, verapamil, taurine and  thiamine by SLC transporters has been observed in ARPE-19 cells (for
references see table 8). Interestingly, also several zinc transporters have been found in ARPE-19 cells
and active zinc uptake was recently observed (Leung et al. 2008, Rezaei et al. 2008). Zinc transporters
may not be relevant from the drug delivery point of view, but may have pathophysiological significance.
Table 8. Drug delivery related influx transporters of ARPE-19 cell line
TRANSPORTER FAMILY/MEMBER EXPRESSION FUNCTION REF.
SLC1 Glutamate/neural amino acid transporter
SLC1A1/EAAC1/EAAT3 Prot. Maenpaa et al. 2004
SLC1A5/ASC RNA Bridges et al. 2007
SLC1A6/EAAT4 Prot Maenpaa et al. 2004
SLC5 Sodium glucose cotransporter
SLC5A6/SMVT RNA Uptake of biotin Janoria et al. 2009
SLC5A8/SMCT1 Prot. basolaterally1 Uptake of (14C)nicotinate Martin et al. 2007
SLC6/Sodium and chloride dependent
neurotransmitter
SLC6A6/TAUT Prot. Uptake of taurine
El-Sherbeny et al.2004,
Bridges et al. 2001b
SLC6A14/ATB0,+ RNA Bridges et al. 2007
SLC7/Cationic amino acid transporter, y+
system
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SLC7A5/LAT1 Prot. Uptake of L-leucine Yamamoto et al. 2009
SLC7A8/LAT2 RNA Uptake of L-phenylalanine Gandhi et al. 2004
SLC7A11/xCT system Xc- RNA
Uptake of cystine and
glutamate
Bridges et al. 2001a,
Gnanaprakasam et al. 2009
SLC15/Proton oligopeptide cotransporter
SLC15A4/PHT1 RNA Activity not found Ocheltree et al. 2003
SLC16/Monocarboxylate transporter
SLC16A1/MCT1 Prot apically2 Uptake of lactate
Majumdar et al. 2005;Philp et
al. 2003
SLC16A3/MCT4 Prot. basolaterally2
Majumdar et al. 2005;Philp et
al. 2003
SLC16A8/MCT3 Prot. basolaterally3 Turowski et al. 2004
SLC19/Folate/thiamine transporter
SLC19A1/RFT-1 Prot. apically
Uptake and transport of
folate1,4
Bridges et al. 2002;Chancy et
al. 2000;Naggar et al. 2005
SLC19A2/hTHRT-1 Prot.
SLC19A3/hTHRT-2 Prot. Uptake of thiamine Subramanian et al. 2007
SLC22/Organic cation/anion/zwitterion
transporter
SLC22A3/OCT3 RNA
Uptake of 1-methyl-4-phenyl
pyridinium Rajan et al. 2000
Unknown organic cation transpoter Uptake of verapamil Han et al. 2001
Unknown organic cation transpoter Uptake of brimodine Zhang et al. 2006
SLC28 and SLC29/Nucleoside transporters not studied Uptake of adenosine Majumdar et al.,2004
SLC46/Heme transporter
SLC46A1/PCFT RNA Umapathy et al. 2007
1Filter cultured by method by Dunn et al (2006) 2 cultured for 120 days on 100-mm dishes 3Cultured on porcine lens capsule
4from basal to apical direction
ARPE-19 cells may be a useful model when one is interested in investigating active transport. However,
the in vitro/in vivo correlation in many cases is not known. No, direct conclusions regarding in vivo RPE
transporters cannot be drawn based on a cell model. While in vivo data (expression and functionality)
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represents definitive proof, it is usually lacking and very difficult to obtain. The polarized expression of
transporters and directionality in transport have been shown in the ARPE-19 cell model in some cases.
However due to the higher permeability compared to isolated RPE-choroid, it is possible that active
transport, even when present, may not be always detected in transport studies. Since ARPE-19 cell line
is widely used in retinal research, it is important to know which transporters are expressed and present
in this cell model.
6.3 Future directions
There are several open questions related to the drug delivery to the posterior eye segment tissues e.g.
the effect of aging. Lipid rich deposits (drusens) are found between RPE and Bruch’s membrane normally
in the elderly and they are also associated with AMD. In addition, RPE atrophy is a main feature of AMD.
These changes may affect the transport through BRB. Furthermore, BRB may be compromised after
photocoagulation, due to development of choroidal neovascular membranes and may become leaky in
an infected eye. The disease state and aging related changes in the RPE may have an influence on ocular
pharmacokinetics after intravitreal, transscleral and systemic drug delivery. Therefore further studies on
pathophysiology, pharmacology and drug delivery are needed. Human derived cell culture models are
important tools especially in the case of the eye since there are such limited possibilities to use the
human tissue.
Systematic characterization of the cells in different culture conditions is a prerequisite before the cell
model can be established as a drug testing tool. Systems free from biological material from other species
like serum free culture media and synthetic growth membranes are more easily controlled than
biological material and may avoid problems related to cross species reactions. It may be possible to
modify the cell properties also by applying gene transfer technology.
Recently, it has become clear that the intravitreal injections are feasible in clinical practice, but in most
cases, frequent injections are needed. Prolonged action drug delivery methods would decrease the
number of needed injections. In this study, gene transfer resulted in prolonged protein secretion from
the ARPE-19 cells suggesting that gene transfer may be a viable approach for achieving prolongation of
the effects of the therapeutic proteins, but this approach requires resolution of  other problems
inherent to intravitreal gene delivery e.g. DNA complex diffusion in the vitreous and neural retina. Other
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possibilities for effect prolongation include implants and the use of particulate systems with slow
releasing properties.
There are several ophthalmic drugs that may interact with transporters. The clinical significance of
transporter proteins remains to be clarified. Similarly, the roles of transporter polymorphisms and the
potential of transporter mediated drug targeting demand further exploration. The well-known species
differences in transporter proteins emphasis the need to utilize human derived material.
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7 CONCLUSIONS
In this study, filter cultured ARPE-19 cells were characterized as a cell model of outer BRB for use in drug
delivery studies.
The specific conclusions of the study are:
1. Filter cultured ARPE-19 model formed a tight monolayer, but passive permeability of the cell model
was higher than in the isolated bovine RPE-choroid. The cell model was able to classify the
characteristics of several compound based on their lipophilicity and molecular size.
2. The barrier properties of the ARPE-19 cell culture model were not enhanced by growth medium
supplementations.
3. RPE related gene expression was up-regulated in filter culture. In filter cultures, the composition of
the cell culture medium had only minor effects on RPE related gene expression.
4. The directionality in active transport was quantively, but not quantitatively similar in the ARPE-19
cell model and in isolated bovine RPE/choroid tissue. The higher passive permeability of cell model
may lead to relative underestimation of active transport.
5. MRP1, MRP4 and MRP5 efflux proteins were expressed in the ARPE-19 filter culture model. The
expression pattern was shared with primary RPE cells. In contrast, D407 cells were found to express
also MRP2 and BCRP proteins. The results indicate MRP1 and MRP5 efflux protein activity in the
ARPE-19 cells.
6. The calcein-AM assay suggested that Hsp the inhibitor, radicicol, interacted with the MRP1 efflux
protein.
7. Prolonged gene expression in the filter grown ARPE-19 cells was achieved with lipoplexes. The filter
grown cell model, with non-dividing cells displaying the properties of differentiated RPE cells,
resembles in vivo RPE.
8. According to the literature, membrane transporters belonging to 11 transporter families are found
in the ARPE-19 cell model and some of them are known to transport ophthalmic drugs. Many
ophthalmic drugs are known to be transporter substrates, but in very few cases has the expression
of these transporters been studied in RPE.
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Retinal pigment epithelium (RPE) 
has an essential role in ocular phar-
macokinetics. In this study an in 
vitro model of RPE was character-
ized. The barrier properties and 
active transport between the model 
and ex vivo tissue were comparable. 
Expression of eight efflux transport-
ers was studied in four different 
RPE models. Multidrug resistance 
associated proteins 1, 4 and 5 were 
constantly expressed. In addition, 
literature data of influx transport-
ers of RPE models and RPE in vivo 
is summarized and the role of mem-
brane transporters in ocular phar-
macokinetics discussed. 
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